MarketPeel
Insider Trading Intelligence
LG

Linda Grais

CRVS
DIRECTOR · CORVUS PHARMACEUTICALS, INC. · CIK 0001413306
FILING MIX · LIFETIME100%/0%
BUYS
12
SELLS
0
TOTAL VALUE
$24.5K
COMPANIES
1
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
15,000
AVG SELL PX
TRADE KIND
SHOWING 12 / 12
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Linda Grais, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+29.61%+1.40%+28.22%+28.22%
14d1+100.00%+18.85%+1.74%+17.11%+17.11%
30d1+100.00%+28.85%+5.85%+22.99%+22.99%
60d1+0.00%-5.38%+9.19%-14.57%-14.57%
90d1+0.00%-14.23%+8.90%-23.13%-23.13%
180d1+0.00%-46.54%+7.46%-53.99%-53.99%
1y1+0.00%-13.08%+28.54%-41.62%-41.62%
2y1+100.00%+39.23%+46.17%-6.94%-6.94%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CRVS · 15,000 shares · as of Jun 11, 2026
03,7507,50011,25015,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 12 buys / 0 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 11, 2026Jun 15, 2026View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 12, 2025Jun 16, 2025View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 13, 2024Jun 17, 2024View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Dec 6, 2023Dec 8, 2023View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 15, 2023Jun 20, 2023View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
10,000$2.45$24.5K10,000May 15, 2023May 16, 2023View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Aug 11, 2022Aug 15, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 15, 2022Jun 17, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Sep 9, 2021Sep 13, 2021View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 15, 2021Jun 16, 2021View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 9, 2020Jun 12, 2020View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Mar 19, 2020Mar 20, 2020View →
Other insiders · CRVS
Loading peer insiders…
About this filer
CIK 0001413306
ROLE
Director
PRIMARY
CRVS
COMPANIES
1
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001413306DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback